ADHF

WhiteSwell Announces Six-month Outcomes After eLym System Treatment for Acute Decompensated Heart Failure Patients in its DELTA-HF Study

Retrieved on: 
Wednesday, March 6, 2024
Medical Devices, Health, Surgery, Clinical Trials, Cardiology, Biotechnology, Peripheral edema, Thoracic duct, Acute decompensated heart failure, Ohio State University, Physiology, Drainage, Congestion, Heart failure, ADHF, Cell biology, Death, Patient, Lymphatic system, Medicine, THT, Tissue, Pharmaceutical industry

WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), announced today positive six-month follow-up data on the initial nine patients treated in its ongoing DELTA-HF trial evaluating the WhiteSwell eLym™ System.

Key Points: 
  • WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), announced today positive six-month follow-up data on the initial nine patients treated in its ongoing DELTA-HF trial evaluating the WhiteSwell eLym™ System.
  • Nine hospitalized patients with ADHF received eLym therapy in conjunction with diuretic therapy and were followed for six months.
  • Reduced rehospitalizations: Comparing patients’ clinical course before and after eLym therapy, in the six months prior to eLym therapy there were 13 heart failure related hospitalizations, while in the six months after eLym therapy there were just two heart failure hospitalizations and one heart failure related death, for a 77% reduction.
  • The minimally invasive catheter system was successfully deployed and removed in all patients, with a mean treatment time of 24 hours.

Reprieve Cardiovascular Emerges from Stealth Mode after $42 Million Series A Financing to Bring Intelligent Fluid Management to Heart Failure Patients

Retrieved on: 
Tuesday, February 20, 2024
Health, Medical Devices, Health Technology, General Health, Clinical Trials, Cardiology, Biotechnology, Volume overload, Pacyna, Diuretic, Physician, Acute decompensated heart failure, Leg, Standard of care, Heart failure, ADHF, FASTR, Reprieve, Fatigue, Patient, Medtronic, Circulatory system, Pharmaceutical industry

Reprieve Cardiovascular , Inc., a development stage company focused on pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment, today announced it has raised a total of $42 million in series A financing.

Key Points: 
  • Reprieve Cardiovascular , Inc., a development stage company focused on pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment, today announced it has raised a total of $42 million in series A financing.
  • The total round was co-led by Lightstone Ventures and Sante Ventures and joined by Deerfield Management, Genesis Capital, and Arboretum Ventures.
  • The funding will advance the Company’s clinical and development programs, including the ongoing FASTR trial and its upcoming pivotal trial.
  • Pacyna continued, “Reprieve Cardiovascular is bringing intelligent decongestion management to heart failure patients.

New Randomized Controlled Trial Demonstrates the Efficacy of Daxor’s BVA Guided-Care in Heart Failure Patients

Retrieved on: 
Monday, November 13, 2023
ADHF, RCT, An Inaccurate Memoir, Acute decompensated heart failure, Pennsylvania Convention Center, Duke University, Plasma, American Heart Association, Anemia, Patient, Tree volume measurement, Heart failure, NIH, Diagnosis, Biomarker, BVA, Medical imaging, Boston

Oak Ridge, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the presentation of data from a Phase I National Institute of Health (NIH) sponsored randomized control trial (RCT) from two Veterans Affairs Medical Centers (Boston , Minneapolis), validating treatment decisions guided by the Company’s BVA-100® diagnostic blood test benefitted patients with acute decompensated heart failure (ADHF). Data were presented at the American Heart Association Scientific Sessions 2023 at the Pennsylvania Convention Center in Philadelphia, PA on November 11, 2023.

Key Points: 
  • Data were presented at the American Heart Association Scientific Sessions 2023 at the Pennsylvania Convention Center in Philadelphia, PA on November 11, 2023.
  • Data showed that on average 7 out of 10 ADHF patients are not being accurately diagnosed.
  • Clinical assessments of volume status and anemia were collected for all patients prior to BVA measurement at hospital admission and post-discharge.
  • Patients in the BVA-guided arm received treatment informed by the BVA test results, in the blinded arm volume was only assessed using clinical tools and biomarkers absent the BVA results.

Truveta announces availability of millions of echocardiogram reports to advance cardiovascular research

Retrieved on: 
Wednesday, November 8, 2023
ADHF, Peripheral artery disease, Moyamoya disease, MD, Organization, Transthoracic echocardiogram, Health, Journal, Pulmonary embolism, TLM, Risk, Pulmonary hypertension, Stenosis, Reprieve, Acute decompensated heart failure, EHR, Society, AI, Patient, Boston Scientific, PAD, Heart failure, Pharmaceutical industry

BELLEVUE, Wash., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Today Truveta announced the availability of more than 56.6 million clinical observations from more than 2.7 million echocardiogram reports from more than 1.7 million de-identified patients, making it the market leader in real-world data to advance cardiovascular research at scale.

Key Points: 
  • BELLEVUE, Wash., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Today Truveta announced the availability of more than 56.6 million clinical observations from more than 2.7 million echocardiogram reports from more than 1.7 million de-identified patients, making it the market leader in real-world data to advance cardiovascular research at scale.
  • New peer-reviewed research using Truveta Data was published recently in the Journal of the Society for Cardiovascular Angiography and Interventions (JSCAI) comparing two treatments for pulmonary embolism and identifying risk for adverse events like major bleeding.
  • Existing methods, such as relying on registry data or physician referrals, have limitations in scope and timeliness, hindering large-scale research.
  • The availability of these data has the potential to propel cardiovascular research forward in ways never before possible, opening new horizons of discovery and innovation to improve patient care and outcomes and save lives."

WhiteSwell Announces Successful Treatment of Acute Decompensated Heart Failure Patients in its Early Feasibility DELTA-HF Study

Retrieved on: 
Saturday, October 7, 2023
Health, Clinical Trials, Cardiology, Medical Devices, ADHF, Heart Failure Society of America, Lymphatic system, Acute decompensated heart failure, Feasibility, Risk, ICCU, Creatinine, Ohio State University Wexner Medical Center, Cell biology, Congestion, Ohio State University, Thoracic duct, Kidney, Heart failure, Safety, Patient, Tissue, Drainage, Pharmaceutical industry, Medical imaging, Physiology

WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), announced today positive initial results from its ongoing DELTA-HF trial evaluating the WhiteSwell eLym™ System.

Key Points: 
  • WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), announced today positive initial results from its ongoing DELTA-HF trial evaluating the WhiteSwell eLym™ System.
  • The data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023 in Cleveland, Ohio.
  • Nine hospitalized patients received eLym therapy in conjunction with diuretic therapy, while six patients received standard of care treatment with loop diuretics alone.
  • “It cannot be overemphasized how significant and challenging it is to fully decongest patients hospitalized with decompensated heart failure.

Aortix Pump Therapy Leads to Rapid Decongestion and Improved Kidney Function in Hospitalized Patients with Heart Failure and Worsening Renal Function

Retrieved on: 
Tuesday, March 21, 2023
Heart, Congestion, Acute decompensated heart failure, Heart failure, MI, CRS, Perfusion, ADHF, FACC, Patient, Swelling, Cardiorenal syndrome, Blood, Abdomen, Mortality, THT, Military Hospital 4/637, Fatigue, Pharmaceutical industry, Medical device, MD

These patients, who were unresponsive to available medical therapy, demonstrated significant improvements in kidney function, cardiac function, and patient-reported assessment of shortness of breath at 30 days after treatment with the Aortix pump.

Key Points: 
  • These patients, who were unresponsive to available medical therapy, demonstrated significant improvements in kidney function, cardiac function, and patient-reported assessment of shortness of breath at 30 days after treatment with the Aortix pump.
  • The results from the CRS pilot study were presented today during the late-breaking clinical science session at the Technology and Heart Failure Therapeutics (THT) conference in Boston.
  • The consistent results indicate the potential of Aortix therapy to be a major therapeutic advancement for CRS patients.
  • The innovative design uses intra-aortic placement and harnesses fluid entrainment to pump blood without the need of a valve and provides physiologically natural delivery of therapy.

Nuwellis Announces Peer-Reviewed Publication of Clinical Trials Analysis Advocating the Use of Ultrafiltration for Heart Failure Patients Resistant to Diuretics

Retrieved on: 
Tuesday, March 21, 2023
Diuretic, Acute decompensated heart failure, IV, Expansion, Ultrafiltration, ADHF, Burn, History, Hospital, Publication, Patient, Pharmaceutical industry

The publication highlights the scale of clinical burden: “ADHF has the highest rate of hospital readmissions among all medical conditions and portends a significant financial burden on healthcare systems worldwide.”1

Key Points: 
  • The publication highlights the scale of clinical burden: “ADHF has the highest rate of hospital readmissions among all medical conditions and portends a significant financial burden on healthcare systems worldwide.”1
    The publication , “Extracorporeal Ultrafiltration for Acute Heart Failure,” featured in Cardiorenal Medicine Journal, includes the review of pooled data from seven randomized controlled trials of ultrafiltration with a total of 771 patient participants.
  • “In the last six months we have announced various new publications demonstrating results that favor ultrafiltration over IV diuretics when using Nuwellis’ Aquadex system.
  • This publication is different because it outlines the reasons why healthcare providers should use ultrafiltration and the consequences of not using it to treat ADHF.
  • We look forward to increased sales momentum as we expand awareness of the benefits of ultrafiltration over diuretics using the arguments presented by the authors.”

scPharmaceuticals Announces Data Presentations at the Heart Failure Society of America 2022 Annual Scientific Meeting

Retrieved on: 
Friday, September 30, 2022
Adult, Dialysis, Hospital, Congestion, AT, Trial of the century, COVID-19, Infection, Risk, SLOS, Company, Poster, Private Securities Litigation Reform Act, NDA, Heart failure, Patient, Length of stay, U.S. Securities and Exchange Commission, NIS, ADHF, Acute decompensated heart failure, Solution, Annual report, Diagnosis, Healthcare Cost and Utilization Project, NYHA, Security (finance), Pharmaceutical industry

If approved, FUROSCIX has the potential to provide an outpatient alternative for the treatment of worsening heart failure due to congestion.

Key Points: 
  • If approved, FUROSCIX has the potential to provide an outpatient alternative for the treatment of worsening heart failure due to congestion.
  • scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes.
  • The Companys lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

TCT 2022: Impella Enables Complete Revascularization, Improved Quality of Life and Native Heart Recovery

Retrieved on: 
Tuesday, September 13, 2022
Medical Devices, Health, Surgery, Clinical Trials, Cardiology, Biotechnology, Safety, Patient, Decompensation, U.S. Securities and Exchange Commission, University of Washington, The Valley Hospital, Physician, Nasdaq, Myocardial infarction, MPH, U.S. FDA, Survival, EDT, DO, Heart failure, Doctor of Philosophy, Heart, ABMD, PCI, Royal Brompton Hospital, FDA, Cardiomyopathy, News, ADHF, Cardiogenic shock, Security (finance), Conference, Northside Hospital, Blood volume, Faculty, Harefield Hospital, Program, Ascension Michigan, Mount Sinai Health System, Myocarditis, Quality of life, University of Pennsylvania Health System, Acute decompensated heart failure, Shock, Multimedia, University, STEMI, TCT, Tufts Medical Center, Medical device, Pharmaceutical industry, Abiomed, MD, Impella

(Graphic: Business Wire)

Key Points: 
  • (Graphic: Business Wire)
    During the conference, physician-researchers will present clinical data demonstrating Impella leads to higher survival rates for cardiogenic shock patients and quality of life improvements for heart failure patients.
  • Abiomeds booth will feature the latest Impella technology, including Impella 5.5 with SmartAssist and Impella RP with SmartAssist .
  • Future pipeline technology will be available to preview, including Impella ECP , Impella RP Flex, Impella BTR and preCARDIA .
  • Impella 2.5, Impella CP, Impella CP with SmartAssist, Impella 5.0, Impella LD and Impella 5.5 with SmartAssist are U.S. FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.

Cardionomic Announces First Patient Enrolled in STIM-ADHF Study

Retrieved on: 
Thursday, May 19, 2022
Federal, Hospital, Patient, Weight gain, Hemodynamics, ADHF, Heart rate, Heart, Heart failure, Diuretic, Breathe Me, Pulmonary artery, Medical device

MINNEAPOLIS, May 19, 2022 /PRNewswire/ -- Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce initial enrollment in their STIM-ADHF Study. The study will evaluate therapy optimization and system management of the Cardiac Pulmonary Nerve Stimulation (CPNS™) System in patients suffering from Acute Decompensated Heart Failure (ADHF), defined as new or worsening symptoms of heart failure. The first patient was enrolled by Martin Hudec, MD., PhD., Principal Investigator at SUSCCH, Banská Bystrica, Slovakia. Up to fifty patients are expected to be enrolled worldwide.

Key Points: 
  • MINNEAPOLIS, May 19, 2022 /PRNewswire/ -- Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce initial enrollment in their STIM-ADHF Study.
  • The first patient was enrolled by Martin Hudec, MD., PhD., Principal Investigator at SUSCCH, Bansk Bystrica, Slovakia.
  • Up to fifty patients are expected to be enrolled worldwide.
  • Cardionomic, Inc. is a privately held U.S. company that designs, produces, and markets devices to address heart failure.